Kamran Alam insider trades: Taysha Gene Therapies (TSHA) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Kamran reports to the SEC
Open-market buys and sales
7 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Feb 4, 2026 | TSHA | ↓ Sell | 1,655 | $4.52 | $7K | Direct | Feb 6, 2026 (2d) |
| Jan 26, 2026 | TSHA | ↓ Sell | 102,817 | $4.72 | $485K | Direct | Jan 27, 2026 (1d) |
| Aug 21, 2025 | TSHA | ↓ Sell | 54,491 | $2.85 | $155K | Direct | Aug 22, 2025 (1d) |
| Aug 24, 2023 | TSHA | ↓ Sell | 33,000 | $2.33 | $77K | Direct | Aug 25, 2023 (1d) |
| Aug 23, 2022 | TSHA | ↓ Sell | 3,325 | $3.47 | $12K | Direct | Aug 24, 2022 (1d) |
| Aug 22, 2022 | TSHA | ↓ Sell | 28,675 | $3.70 | $106K | Direct | Aug 22, 2022 (0d) |
| Aug 20, 2021 | TSHA | ↓ Sell | 33,000 | $16.88 | $557K | Direct | Aug 20, 2021 (0d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other TSHA insiders
Open-market trades in the last 12 months
About Kamran Alam's insider trades
Kamran Alam is Chief Financial Officer at Taysha Gene Therapies (TSHA). Since Aug 20, 2021, Kamran has reported no open-market purchases and 7 sales worth $1.4M on SEC Form 4. In the last 12 months: 2 sales ($493K).
Their filings also include grants and awards (12 filings), shares withheld for taxes (2 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every TSHA insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.